Clinical Trial Detail

NCT ID NCT02423343
Title A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

lung non-small cell carcinoma

hepatocellular carcinoma

Advanced Solid Tumor

malignant glioma

Therapies

Galunisertib

Nivolumab

Age Groups: adult

No variant requirements are available.